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ABSTRACT
Despite of the great advances in anti-hypertensive therapies, many patients 
under Renin-Angiotensin- System (RAS) suppression develop albuminuria, which is a 
clear indicator of therapeutic inefficiency. Hence, indicators of vascular function are 
needed to assess patients’ condition and help deciding future therapies.
Proteomic analysis of circulating extracellular vesicles (EVs) showed two 
proteins, kalirin and chromodomain-helicase-DNA-binding protein 7 (CHD7), increased 
in albuminuric patients. A positive correlation of both with the expression of the 
endothelial activation marker E-selectin was found in EVs. In vitro analysis using 
TNFα-treated adult human endothelial cells proved their involvement in endothelial 
cell activation.
Hence, we propose protein levels of kalirin and CHD7 in circulating EVs as 
novel endothelial dysfunction markers to monitor vascular condition in hypertensive 
patients with albuminuria.
INTRODUCTION
Albuminuria has been associated with increased 
cardiovascular (CV) risk and allows monitoring 
therapeutic efficiency in hypertensive patients, since a 
substantial number of them develop de novo albuminuria 
despite of the RAS suppression treatment [1]. These 
patients show a characteristic inflammatory signature in 
both plasma [2, 3] and urine [4]. In this context, increased 
shear stress, endothelial dysfunction [5] and oxidative 
stress [6] in the whole circulatory system arises and 
therefore additional therapies need to be addressed to 
prevent future events and avoid organ damage. 
EVs are membrane vesicles released by secreting 
cells to communicate with other cells. These vesicles 
are a very useful tool to understand the processes taking 
place in the secreting cell, especially in pathological 
conditions, in which its release is enhanced [7]. EVs 
include two different types of vesicles: 1) microvesicles 
(MVs), 50 nm-1 μm vesicles which bud directly from the 
plasma membrane; and 2) exosomes: 50–120 nm vesicles 
released by fusion of multivesicular endosomes (MVEs) 
to the plasma membrane [8]. EVs derived by either 
platelets (PEVs) or endothelial cells (EEVs) are shed to 
the bloodstream and increased number of both has been 
associated with increased CV risk [9]. Furthermore, an 
increased number of apoptotic EEVs has been recently 
reported in hypertensive patients with albuminuria [10] 
and increased shear stress might be the major cause of 
such increase.
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Circulating EVs may therefore constitute a low-
invasive tool for analysing the pathogenic processes 
triggered by albuminuria. Using differential proteomic 
analysis we have been able to identify kalirin and CHD7 
to be increased in EVs from albuminuric patients. 
In vitro analysis showed and proved their involvement 
in endothelial cell (EC) activation within blood vessels. 
Thus, we propose protein levels of kalirin and CHD7 in 
circulating EVs as novel endothelial dysfunction markers 
in hypertensive patients with albuminuria. 
RESULTS
Efficient isolation of EVs from blood of 
hypertensive patients
The EV fraction obtained after isolation by 
ultracentrifugation was checked by Electron Microscopy 
(EM) confocal microscopy and flow cytometry. EM results 
showed presence of vesicles ranging from 50 nm – 1 µm 
size, which corresponded to both exosomes and MVs 
(Figure 1, A1 and A2). Most abundant CD61+ PEVs were 
imaged by confocal microscopy (Figure 1B) and these, 
together with CD61−/CD31+ EMVs were detected by flow 
cytometry (Figure 1C). 
Differential analysis of EVs from hypertensive 
patients with albuminuria
Differential abundance analysis was performed by 
means of iTRAQ labelling and LC-MS/MS. To focus 
in the alterations occurring with albuminuria onset, two 
different groups attending to albuminuria development 
were independently analysed: a) patients developing de 
novo albuminuria during follow-up (dnA); b) patients 
with sustained albuminuria during follow-up (SA) and a 
nomoalbuminuric group was used as control (N). Table 1 
Results showed 20 proteins significantly altered, among 
which 19 were found in any of the albuminuric groups, 
compared to the normoalbuminuric (Supplementary 
Table S1). A principal component analysis (PCA) and 
heatmap (Figure 2A and 2B) were performed using these 
differential proteins. In the PCA (Figure 2A) the first 
principal component greatly separates normoalbuminuric 
patients from the albuminuric patients, showing that 
the EVs from normoalbuminuric patients express very 
different levels of proteins to those of the albuminuric. All 
proteins were searched in two EVs databases: Vesiclepedia 
and EVpedia, for prior evidence of expression by EVs, 
either MVs or exosomes. Fourteen of them have been 
previously reported to be expressed by EVs at the 
Figure 1: Isolation of EVs from blood plasma of hypertensive patients. Electron microscopy allowed to check presence 
of all range of EVs: (A1), (15,000× magnification, scale bar 2 µm) vesicles of 0.1–1 µm size (microvesicles, MVs). (A2), (200,000× 
magnification, scale bar 100 nm) vesicles of 40–100 nm, corresponding to exosomes as well as a small MV in the centre. (B) Confocal 
microscopy analysis of CD61 allowed checking for the presence of platelet-derived MVs, which are the most abundant in the blood (63× oil 
immersion objective, 1.4 zoom. Scale bar 1 µm). (C) Flow cytometry analysis was performed after defining a gate for EVs using Megamix 
beads. EVs expressing CD61 (platelet-derived) and CD61−/CD31+ (endothelial-derived) were detected in the isolated fraction.
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Table 1: Baseline characteristics and medications of the patients recruited for discovery and 
confirmation phase
Discovery phase
 N (n = 8) dnA (n = 7) SA (n = 7) P-value
Age (years) 62 ± 6 63 ± 11 62 ± 10 0.79
Sex (male), % 50 70 70 0.6
BMI (kg/m2) 30 ± 4 32 ± 4 30 ± 5 0.96
Current smoking, % 0 0 30 0.095
Total cholesterol (mg/dl) 194 ± 27 159 ± 16 182 ± 43 0.046
Triglycerides (mg/dl) 86 ± 22 97 ± 30 134 ± 77 0.13
HDL cholesterol (mg/dl) 56 ± 14 48 ± 8 47 ± 11 0.19
LDL cholesterol (mg/dl) 121 ± 28 92 ± 15 108 ± 31 0.04
Glycaemic (mg/dl) 100 ± 15 101 ± 16 106 ± 31 0.54
Uric acid (mg/dl) 4.6 ± 1.1 6 ± 2 6 ± 2 0.18
Creatinine clearance rate (mg/ml) 88 ± 22 114 ± 50 84 ± 43 0.48
eGFR (ml/min/1.73m2) 83 ± 13 68 ± 23 67 ± 28 0.29
Systolic blood pressure (mmHg) 126 ± 9 136 ± 24 124 ± 13 0.95
Diastolic blood pressure (mmHg) 75 ± 10 81 ± 4 75 ± 11 0.93
Medications
Antihypertensives, %
 ACEi 12 12 0 0.58
 ARB 88 88 100 0.58
 Diuretic 88 57 72 0.74
 Calcium channel blocker 75 63 15 0.13
 Beta blocking agent 25 29 29 0.98
 Alpha blocking agent 13 14 14 0.3
Other treatments, %  
Anticoagulant agent 0 29 29 0.24
Lipid lowering agents 88 72 57 0.41
Antidiabetic agent 0 14 0 0.32
Confirmation phase
N (n = 50) dnA (n = 25) SA (n = 24) P-value
Age (years) 65 ± 11 68 ± 8 64 ± 12 0.23
Sex (male), % 38 64 67 0.024
BMI (kg/m2) 30 ± 4 29 ± 5 30 ± 4 0.6
Current smoking, % 10 20 13 0.48
Total cholesterol (mg/dl) 186 ± 29 165 ± 26 174 ± 28 0.007
Triglycerides (mg/dl) 123 ± 51 140 ± 66 141 ± 71 0.38
HDL cholesterol (mg/dl) 54 ± 12 51 ± 13 47 ± 14 0.06
LDL cholesterol (mg/dl) 107 ± 28 86 ± 17 101 ± 21 0.002
Glycaemic (mg/dl) 120 ± 41 128 ± 26 118 ± 34 0.57
Uric acid (mg/dl) 5 ± 2 6 ± 2 7 ± 2 0.0003
Creatinine clearance rate (mg/ml) 99 ± 41 86 ± 46 75 ± 37 0.017
eGFR (ml/min/1.73m2) 80 ± 17 70 ± 22 67 ± 27 0.086
Systolic blood pressure (mmHg) 138 ± 17 136 ± 17 142 ± 29 0.64
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protein level, while the mRNA of another 4 (MAGUK 
p55 subfamily member 4, MPP4; ORM1-like protein 2, 
ORML2; CHD7; and XK-related protein 3) was shown 
to be carried by these vesicles (Supplementary Table S1). 
Two proteins have never been associated with EVs before 
(Ubiquitin carboxyl-terminal hydrolase, CYLD; and 
biorientation of chromosomes in cell division protein 
1-like 1). Thus, we provide new evidence of the expression 
of 6 proteins in EVs. Results from all quantified proteins 
in EVs are shown in Supplementary Table S2. 
Confirmation by SRM of the increased 
abundance of kalirin and CHD7 in EVs from 
hypertensive patients with albuminuria and 
analysis of correlation with E-selectin
Kalirin and CHD7 were analysed by SRM together 
with the cellular marker of activated ECs, E-selectin 
(CD62E). Quantification of these proteins was performed 
in an independent cohort of 99 patients: 49 albuminuric 
(25 dnA, 24 SA) and 50 normoalbuminuric. Both kalirin 
and CHD7 were found to significantly increase in dnA 
(Figure 2C and Table 2). The former was increased in SA 
in a similar way, while levels of CHD7 in SA were similar 
to those of normoalbuminuric patients. A significant 
positive correlation of both proteins with CD62E was 
found in EVs (Table 2). 
In vitro analysis of the expression of kalirin and 
CHD7 in TNF-α treated ECFCs
In order to test the hypothesis that kalirin and CHD7 
would increase in blood vessel ECs upon activation, ECs 
were isolated from human saphenous vein. These primary 
cultures provided us with an in vitro model of adult blood 
vessel ECs, which might be more reliable than commonly 
used human umbilical vein ECs (HUVECs). Expression of 
CD62E and CD106 was substantially increased in TNF-α 
treated cells compared to untreated controls as shown by 
flow cytometry (Figure 3A). Flow cytometric analysis 
of kalirin and CHD7 in TNF-α treated cells showed a 
significant increase in the expression of both proteins 
(p < 0.001) in all activated cells (CD62E+, CD106+ and 
CD62E+/CD106+) as compared to the double negatives 
(CD62E-/CD106−) (Figure 3B). Immunocytofluorescence 
analysis of kalirin and CHD7, together with both activation 
markers showed similar results to those observed by flow 
cytometry and proved expression of the two proteins in 
ECs (Figure 3C) as well as in EVs budding from TNF- α 
activated cells (Figure 4A and 4B).
DISCUSSION
The development of albuminuria during RAS 
suppression involves increased shear stress [11], which 
triggers endothelial activation and subsequent dysfunction 
[5]. Besides, an increased oxidative stress has been 
shown to occur in these patients [6]. Reactive oxygen 
species (ROS) decrease endothelial nitric oxide (NO) 
bioavailability [12], which also results in endothelial 
dysfunction. On the other hand, endothelial activation 
occurring in the kidney from hypertensive patients leads 
to endothelial damage which reduces albumin filtration 
and provokes albuminuria [13]. For all these reasons, new 
indicators of albuminuria progression are needed to better 
characterize vascular condition of hypertensive patients. 
In this sense, analysis of proteins carried by circulating 
EVs seems a very interesting approach, since shear stress 
enhances release of EEVs [14] resulting in increased 
levels in the bloodstream of albuminuric patients [10]. 
Diastolic blood pressure (mmHg) 81 ± 11 81 ± 11 84 ± 15 0.69
Medications
Antihypertensives, %
 ACEi 14 16 20 0.80
 ARB 86 84 80 0.80
 Diuretic 46 60 67 0.2
 Calcium channel blocker 64 60 75 0.51
 Beta blocking agent 26 32 30 0.86
 Alpha blocking agent 18 32 17 0.31
Other treatments, %  
 Anticoagulant agent 40 48 25 0.24
 Lipid lowering agents 74 76 84 0.67
 Antidiabetic agent 28 46 28 0.36
Values are expressed as mean ± SD or percentages (%). P-value was calculated using one-way ANOVA. BMI: body mass index; HDL: high-density 
lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate. N: normoalbuminuria; dnA: de novo 
albuminuria; SA: sustained albuminuria.
Oncotarget15557www.impactjournals.com/oncotarget
Using a proteomics approach, we found 2 proteins, 
kalirin and CHD7, increased in patients developing dnA, 
which therefore may be indicators of the appearance 
of albuminuria in hypertensive patients under RAS 
blockage. Besides, a positive correlation of kalirin and 
CHD7 with the endothelial activation marker CD62E 
was also found. This result suggested these 2 proteins 
may be released by endothelial cells upon activation via 
EVs. We could confirm a significant increase in levels of 
kalirin and CHD7 in activated ECs in vitro. This proves 
an involvement of both proteins in endothelial cell 
activation within blood vessels and explains the observed 
increase in EVs from albuminuric patients, considering 
the inherent endothelial dysfunction associated.  The 
results obtained in vitro showed a similar increase of 
CHD7 and kalirin upon EC activation, but a recovery 
in CHD7 up to normal levels was found in SA patients, 
which point to a different behaviour of both proteins. 
CHD7 seems to be an acute marker of endothelial 
dysfunction, which explains the increase in de novo 
albuminuria and the recovery in sustained albuminuria. 
On the other hand, kalirin seems to be a more general 
indicator of endothelial damage as increases in both 
albuminuric groups. 
Figure 2: EVs from hypertensive patients with albuminuria exhibit increased levels of kalirin and CHD7. (A) differential 
analysis of EVs within N, dnA, and SA groups was performed by iTRAQ and LC-MS/MS. Proteins with log2 of Fold-change (Zq) values 
± 1.5 (Fold-change = 3) were considered differentially expressed. PCA was performed using these differential proteins. The first principal 
component greatly separates normoalbuminuric patients from the albuminuric patients, showing the EVs from normoalbuminuric patients 
express very different levels of proteins to those of the albuminuric. (B) Heatmap showing relative quantifications of the significant 
proteins. (C) Quantification of kalirin and CHD7 was performed by SRM in an independent cohort of 99 patients: 49 albuminuric (25 dnA, 
24 SA) and 50 normoalbuminuric. The increase observed in albuminuric patients in the discovery phase was confirmed for both proteins. 
Values are expressed as mean ± SEM.
Table 2: Results from the SRM confirmation analysis
Protein Alter. ANOVA Ratio dNA_N Tukey Ratio SA_N Tukey Ratio SA_dnA Tukey CD62E Correl.
Kalirin
↑dnA_N
↑SA_N
0.0007 1.55 0.0064 1.68 0.0014 1.09 NS p = 5.96E
-11
R2 = 0.59
CHD7
↑dnA_N
↓SA_N
0.0193 1.56 0.0282 0.99 NS 0.64 0.0495 p = 3.02E
-08
R2 = 0.52
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Kalirin, also called Duo, is involved in signal 
transduction. Its gene has been associated with 
susceptibility of coronary artery disease [15] and ischemic 
stroke [16]. Its expression by VSMCs has been associated 
with neointimal hyperplasia in mice [17]. Here we provide, 
for the first time, evidence of the expression of kalirin in 
human ECs and of its involvement in processes leading to 
endothelial dysfunction. Kalirin is known to inhibit iNOS 
[17, 18] and the hypothesis that it may also suppress NO 
availability in the endothelium by inhibiting eNOS is 
reasonable and deserves further research. Interestingly, 
NO release by ECs has been shown to decrease the release 
of EEVs [14] and therefore a potential inhibition of NO 
production triggered by kalirin is in accordance with both 
the observed augment in activated ECs and circulating 
EVs from albuminuric patients.
There is not much information to date about protein 
CHD7 which functions as a transcriptional activator [19]. 
It is crucial during embryogenesis and has been involved 
in heart and great vessel development [19, 20]. Mutations 
in Chd7 gene are responsible for CHARGE syndrome, 
in which, heart and vascular system are impaired [21]. 
Therefore, CHD7 is deeply involved in cardiovascular 
system development and its correct function may be 
important for a good cardiovascular condition. In our 
work, increased expression of CHD7 by EVs has been 
linked to albuminuria and endothelial activation. Indeed, 
to date, there was no evidence of the expression of CHD7 
Figure 3: Kalirin and CHD7 are increased in endothelial cells upon activation. Cells were treated with TNF-α or EC-medium 
alone for 5 h. (A, B) After activation, cells were trypsinized and labelled 1 h with the surface antibodies CD62E-APC and CD106-PE. 
After this, cells were fixed using 4% paraformaldehyde and permeabilized before incubating 90 min at 4°C with primary antibodies for the 
intracellular proteins kalirin and CHD7. All samples were analysed in a FACS CANTO II (BD Biosciences).A, Flow cytometry of TNF-α 
shows increased expression of the activation markers CD62E and CD106. B, Analysis of TNF-α activated cells by flow cytometry proved 
a significant increase of both kalirin and CHD7 in cells expressing CD62E and/or CD106. Control cells for this experiment were CD62-/
CD106-. (C) Cells were fixed using 4% paraformaldehyde, permeabilized and labelled with CD62E-APC and CD106-PE as well as with 
either of the primary antibodies for kalirin or CHD7. After this, coverslips were incubated with a donkey anti-rabbit secondary antibody 
conjugated with Alexa-488 and Hoechst dye. Cells were visualized in a TCS SP5 confocal microscope (Leica). Immunofluorescence 
analysis of TNF-α treated cells confirmed the increase of kalirin (C1) and CHD7 (C2) in cells expressing any or both of the activation 
markers. All experiments were performed with at least n = 3. Values are expressed as mean ± SEM. KALRN: kalirin, E-selectin = CD62E, 
VCAM-1 = CD106. 
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by ECs, which we hereby have proved by both flow 
cytometry and immunofluorescence. 
A limitation of our study might be the lack of sex 
matching among populations in the confirmation phase. 
We have anyway taken into consideration the existing 
differences in the correlation of albuminuria levels and 
disease state by adjusting albuminuria ranges according 
to gender, as a way of correcting this limitation. Further 
studies in greater cohorts will allow to assess potential of 
these biomarkers and evaluate influence of gender.
The hereby presented results support a potential 
involvement of kalirin and CHD7 proteins in human blood 
vessel endothelial dysfunction and show an increased 
expression of both by circulating EVs in albuminuric 
patients (Figure 4C). Hence, we propose levels of 
these proteins in circulating EVs as novel endothelial 
dysfunction markers to monitor vascular condition in 
hypertensive patients with albuminuria.
MATERIALS AND METHODS
For more details of the experimental procedures, 
please see Supplementary material.
Patients’ recruitment
Patient selection and classification was previously 
described [1–4]. Briefly, 121 patients hypertensive 
patients with (n = 63) or without albuminuria (n = 58) 
were recruited between January 2012 and June 2013 after 
being followed for a minimum period of 3 years with 
visits to the Hypertension Unit, Hospital Universitario 
12 de Octubre, Madrid, Spain; at least, every 6 months. 
After that, the patients continued with their annual 
revisions. Patients were classified according to high 
albuminuria development during follow-up in 3 groups: 
(a) patients with persistent normoalbuminuria (N, n = 
58); (b) patients developing de novo albuminuria during 
follow-up (dnA, n = 32); (c) patients with sustained 
albuminuria during follow-up (SA, n = 31). Characteristics 
and medications of the specific cohorts recruited for the 
discovery and confirmation phase are given in Table 1 
A human saphenous vein from revascularization surgery at 
Hospital Virgen de la Salud, Toledo, Spain; was collected 
for isolation of the ECs addressed for primary cultures. 
The study was conducted according to 
recommendations of Declaration of Helsinki and approved 
Figure 4: EVs from endothelial cells express kalirin and CHD7. Immunofluorescence analysis of kalirin and CHD7 (green), 
CD62E (red) and CD106 (white) of TNF-α activated cells showed proved the expression of kalirin (A) and CHD7 (B) proteins by EVs. (C) 
Schematic conclusion. Overexpression of Kalirin and CHD7 proteins by activated endothelial cells due to increased shear stress may result 
in the observed increase in circulating EVs of hypertensive patients with albuminuria.
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by the local Ethics Committee. Informed consent was 
requested from subjects prior to inclusion in the study.
Extracellular vesicles (EVs) isolation
EVs were isolated as previously described [22], with 
minor modifications. For more details see Supplementary 
material.
Electron microscopy (EM)
The precipitate of EVs obtained by ultracentrifugation 
was fixed in paraformaldehyde 4% and visualized after 
negative staining in a JEM 1010 (JEOL Peabody, MA, 
USA).
iTRAQ labelling
To focus in the alterations occurring with 
albuminuria onset, two different groups attending to 
albuminuria development were independently analysed 
(dnA and SA, n = 14, 7 of each group). A nomoalbuminuric 
group (n = 8) was used as control. In order to analyse 
four samples per group, EVs from 2 patients were pooled 
when necessary. Two different 8-plex experiments were 
performed to process all the analysed sample pools. In 
every experiment two reference samples, each composed 
of a pool of 4 samples obtained from healthy blood donors, 
were labelled with the tags 113 and 117, in order to 
normalize quantifications and secure accurate comparison 
of samples between experiments. The tags addressed to 
label every sample are available on Supplementary Table 
S3.
LC-MS/MS and differential analysis
Labelled peptide samples were analysed by LC-
MS/MS in a Q-Exactive mass spectrometer (Thermo 
Fisher Scientific). Protein quantification from reporter ion 
intensities and statistical analysis were performed using 
QuiXoT software. All the significant proteins found in 
the differential analysis were searched against two EVs 
databases: Vesiclepedia and EVpedia in order to find 
previous evidence of their expression in EVs, both MVs 
and exosomes, at the protein or mRNA level.
SRM confirmation
For confirmation, EVs from an independent cohort 
of 99 patients were analysed by SRM: 49 albuminuric 
(25 dnA, 24 SA) and 50 normoalbuminuric. SRM 
transitions (3 per peptide) were monitored during an 
individual sample analysis (SRM peptides analysed 
and settings are shown in Supplementary Table S4 and 
chromatograms in Supplementary Figure S2). 
Isolation and TNF-α activation of ECs
ECs were isolated from human saphenous vein and 
grown as previously described [23]. Endothelial phenotype 
of ECs was checked by flow cytometry and confocal 
microscopy (Supplementary Figure S1). For stimulating 
ECs, cells were seeded at a density of 2.5 × 104 cells/cm2, 
treated with 10 ng/ml tumour necrosis factor- α (TNF-α) 
or EC-medium alone for 5 h.
Flow cytometry
EVs were analysed by flow cytometry using platelet 
marker CD61 (most abundant source of EVs in blood). 
EVs gate was defined using MegaMix SSC Plus beads 
(Biocytex).
For analysing ECs, cells were trypsinized after 
stimulation and labelled with the surface antibodies for 
E-selectin: CD62E-APC; and VCAM-1: CD106-PE as 
well as with either of the intracellular proteins kalirin 
and CHD7; followed by a donkey anti-rabbit secondary 
antibody conjugated with Alexa-488.
All samples were analysed in a FACS CANTO II 
(BD Biosciences). Experiment was repeated 3 times.
Confocal microscopy
For visualizing EVs staining of CD61 or its isotype 
control was assayed. For ECs analysis, cells were seeded 
in coverslips and treated with TNF-α or EC-medium 
alone. Detection of EC activation markers E-selectin and 
VCAM-1 was accomplished, together with either of the 
intracellular staining of kalirin or CHD7 using the same 
antibodies employed for flow cytometry. 
EVs and cells were visualized in a TCS SP5 
confocal microscope (Leica). All experiments were 
performed with n = 3. 
Statistical analysis
Values for patients’ characteristics are expressed 
as means ± standard deviation (SD) or percentages. One-
way ANOVA was used to calculate statistically significant 
differences of the values between different groups. Post-
hoc analysis of significant ANOVA results was performed 
by means of Tukey analysis. In iTRAQ results, we have 
considered differentially expressed those proteins with 
log2 of Fold-change (Zq) values ± 1.5 (Fold-change = 3). 
For in vitro analyses, Student’s T-test was performed and 
each experiment was repeated 3 times.
All statistics were calculated using SPSS 15.0 
software, except for PCA and heatmap, which were done 
with XLSTAT for Excel (Microsoft).
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